The Evolving Role of Colchicine in Coronary Atherosclerosis Management: Timing May Be Everything – American College of Cardiology
Colchicine is an anti-inflammatory drug approved by the Food and Drug Administration for reduction of cardiovascular risk. Low-dose colchicine has shown significant reduction in cardiovascular events in patients with chronic coronary artery disease. Defining the optimal timing of colchicine initiation after a myocardial infarction may better inform its role in reducing recurrent atherosclerotic cardiovascular events. Chronic inflammation plays a role in the pathogenesis of cardiovascular diseases,
